Medicines & supplements – Current GIS Alerts 2026
Found 791 alerts in the Medicines & supplements category. Check batch numbers, shops, and hazard information.
Common hazards in this category
All recalled products
EURESPAL
Unfavourable benefit–risk balance of the active substance fenspiride indicated by non-clinical studies. Potential effects: serious adverse reactions, threat to health or life.
EURESPAL
Unfavourable benefit-risk ratio for the active substance fenspiride; potential public health hazard. Potential effects: serious adverse reactions, risk to health or life.
EURESPAL
Unfavourable benefit-risk balance for the active substance fenspiride, which may pose a public health risk and requires reassessment. Potential effects: serious adverse reactions, risk to health or life.
EUREFIN
Unfavourable benefit–risk ratio for the active substance fenspiride identified from non-clinical studies; an EU review procedure initiated. Potential effects: serious adverse reactions, threat to health or life.
EURESPAL
Unfavourable benefit-risk ratio for the active substance fenspiride; the French agency ANSM initiated an urgent EU re-evaluation procedure. Potential effects: deterioration of health, risk of complications.
EURESPAL
Unfavorable benefit-risk balance of the active substance fenspiride shown in non-clinical studies. Potential effects: threat to patients' health or life.
EURESPAL
Unfavourable benefit-risk balance for the active substance fenspiride, posing a public health hazard. Potential effects: serious adverse reactions, threat to health or life.
EURESPAL
An unfavorable benefit-risk ratio for the active substance fenspiride was identified based on non-clinical studies; an EU review procedure was initiated. Potential effects: deterioration of health, serious adverse reactions.
EURESPAL
Unfavourable benefit-risk ratio of the active substance fenspiride based on non-clinical studies; an urgent EU procedure was initiated due to a public health concern. Potential effects: serious adverse reactions, threat to health or life.
FOSIDAL O SMAKU MALINOWYM
Unfavourable benefit–risk balance for the active substance fenspiride, which may pose a real and highly probable risk to patients’ health or life, even without damage having occurred so far. Potential effects: serious adverse reactions, complications, life‑threatening events.
FOSIDAL O SMAKU POMARAŃCZOWYM
An unfavourable benefit-risk ratio was identified for the active substance fenspiride, associated with a potential, real and highly probable risk to patients’ health or life, requiring immediate action by supervisory authorities. Potential effects: serious adverse reactions, risk to health or life, possible cardiac complications.
FOSIDAL O SMAKU MALINOWYM
Information was obtained about a threat to public health resulting from an unfavourable benefit-risk balance for the active substance fenspiride, which may cause a direct risk to patients’ health or life. Potential effects: serious adverse reactions, complications, threat to health or life.
FENSPOGAL
An unfavorable benefit–risk ratio was identified for the active substance fenspiride, which may pose a real and highly probable risk to patients’ health or life, requiring immediate suspension and prohibition of marketing the product. Potential effects: serious adverse reactions, risk to patient health or life.
ELOFEN
ELOFEN
PULNEO
An unfavorable benefit-risk ratio for the active substance fenspiride, indicating a potential direct threat to patients’ health or life, requiring immediate suspension of marketing and re‑evaluation of treatment safety. Potential effects: serious adverse reactions, threat to health or life, possible treatment complications.
PULNEO
It was found that, based on new non-clinical studies, the benefit-risk ratio for the active substance fenspiride is not favorable, which may pose a real and highly probable threat to patients’ health or life. Potential effects: serious adverse reactions, complications, risk to health or life.
BUDIXON NEB
Out-of-specification results for the content of budesonide-related substances. Potential effects: reduced efficacy or increased risk of adverse reactions.
BENODIL
Out-of-specification results for related substances of budesonide. Potential effects: reduced efficacy or altered safety of use.
BUDIXON NEB
Test results out of specification in archival samples concerning the content of budesonide related substances. Potential effects: reduced efficacy, increased risk of adverse reactions.
What to do if you bought a recalled product?
If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.